Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events. The gene discussed is LAG3; the disease is triple-negative breast carcinoma.